BeyondSpring Inc (BYSI)vsMerck & Company Inc (MRK)
BYSI
BeyondSpring Inc
$0.75
+5.78%
HEALTHCARE · Cap: $31.53M
MRK
Merck & Company Inc
$146.78
-0.19%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3548354% more annual revenue ($66.57B vs $1.88M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
BYSI
Avoid20
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.6%
Fair Value
$13.63
Current Price
$0.75
$12.88 discount
Margin of Safety
-77.2%
Fair Value
$83.04
Current Price
$146.78
$63.74 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BYSI
The strongest argument for BYSI centers on Debt/Equity. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : BYSI
The primary concerns for BYSI are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
MRK carries more volatility with a beta of 0.23 — expect wider price swings.
BYSI is growing revenue faster at 14.3% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (36/100 vs 20/100). BYSI offers better value entry with a 89.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeyondSpring Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?